Clear Street raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $45 from $12 and keeps a Buy rating on the shares after company’s Type B FDA meeting confirmed that no additional clinical trials are required and the current dataset is sufficient for a BLA submission and to establish sonelokimab’s substantial evidence of effectiveness. There is a path to a “compelling label” with Mira efficacy results included alongside the Vela trials, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- MoonLake provides update following positive feedback from U.S. FDA for SLK
- MoonLake Extends Sonelokimab Data in Psoriatic Arthritis: What Investors Should Watch
- FDA moving to one trial for approval could be positve for MoonLake, says Cantor
- FDA to reduce number of trials required for drug approvals, STAT reports
- MoonLake price target lowered to $26 from $30 at H.C. Wainwright